Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study

NCT06794073 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Adenocarcinoma
Digestive System Neoplasms
Liver Neoplasms

Interventions

DEVICE: Multimodal Thermal Therapy

Sponsor

Shanghai Zhongshan Hospital